Seeing Is Believing
Currently out of the existing stock ratings of Christopher Marai, 123 are a BUY (84.83%), 7 are a HOLD (4.83%), 15 are a SELL (10.34%).
Analyst Christopher Marai, carries an average stock price target met ratio of 57.87% that have a potential upside of 65.57% achieved within 389 days. Previously, Christopher Marai worked at NOMURA, OPPENHEIMER.
Christopher Marai’s has documented 294 price targets and ratings displayed on 24 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on CRBP, Corbus Pharmaceuticals at 04-Jun-2020.
Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 6/20/2016. The price target of $60 was fulfilled within 94 days with a profit of $42.15 (236.13%) receiving and performance score of 25.12.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$268
$16.44 (6.54%)
$284
21 days ago
(11-Apr-2025)
9/10 (90%)
$30.23 (12.71%)
41
Buy
$320
$68.44 (27.21%)
$320
23 days ago
(09-Apr-2025)
12/20 (60%)
$76.73 (31.54%)
215
Buy
$500
$248.44 (98.76%)
$500
1 months ago
(02-Apr-2025)
1/25 (4%)
$233.17 (87.39%)
664
Buy
$342
$90.44 (35.95%)
$338
1 months 1 days ago
(31-Mar-2025)
0/5 (0%)
$71.98 (26.66%)
Buy
$345
$93.44 (37.14%)
$295
1 months 1 days ago
(31-Mar-2025)
17/18 (94.44%)
$74.98 (27.77%)
247
What Year was the first public recommendation made by Christopher Marai?